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Abstract: Interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) are key cytokines 
that  drive  the  production  of  inflammatory  mediators  and  matrix-degrading  enzymes  in 
osteoarthritis (OA). These proinflammatory cytokines bind to their respective cell surface 
receptors and activate inflammatory signaling pathways culminating with the activation of 
nuclear  factor  κB  (NF-κB),  a  transcription  factor  that  can  be  triggered  by  a  host  of  
stress-related  stimuli  including,  excessive  mechanical  stress  and  ECM  degradation 
products. Once activated, NF-κB regulates the expression of many cytokines, chemokines, 
adhesion  molecules,  inflammatory  mediators,  and  several  matrix-degrading  enzymes. 
Therefore, proinflammatory cytokines, their cell surface receptors, NF-κB and downstream 
signaling pathways are therapeutic targets in OA. This paper critically reviews the recent 
literature and outlines the potential prophylactic properties of plant-derived phytochemicals 
such as curcumin and resveratrol for targeting NF-κB signaling and inflammation in OA to 
determine whether these phytochemicals can be used as functional foods. 
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1. Introduction 
For the past 160 years human life expectancy has consistently increased by a quarter of a year every 
year [1]. The ―baby boom‖ generation born after World War II have now reached their mid- to late 60s. 
In many European countries one out of every five people is aged 65 and over. According to the 
Organization for Economic Co-operation and Development (OECD) [2], increases in life expectancy 
seen over the last few decades are likely to continue in the future. It is predicted that life expectancy 
will continue to increase by 2.5 years each decade, meaning that the western world’s average life 
expectancy should reach and exceed 100 within the next 50 years  [1]. The increasing human life 
expectancy has resulted in an increase in the prevalence of several diseases. The main four chronic 
diseases  that  the  ageing  population  will  suffer  from  are:  arthritis,  heart  problems,  dementia,  and 
diabetes. The growing burden of arthritic, rheumatic and musculoskeletal diseases will place an even 
greater socioeconomic burden on health systems around the world as the population ages. 
According to the World Health Organization (WHO) [3], orthopedic, rheumatic and musculoskeletal 
conditions comprise over 150 diseases and syndromes, which are usually progressive and associated 
with pain and disability. They can broadly be categorized as joint diseases, physical disability, spinal 
disorders, and conditions resulting from trauma. These conditions are leading causes of morbidity, 
giving  rise  to  enormous  healthcare  expenditures  and  loss  of  productivity.  Knowledge  of  the  key 
determinants of disability in musculoskeletal conditions is critical for reducing their burden on the 
world’s growing population [1,4]. 
The United Nations, the WHO and 37 other countries have proclaimed the years 2000–2010 as the 
Bone and Joint Decade [3,5–7]. This global initiative is intended to improve the lives of people with 
musculoskeletal  disorders,  such  as  arthritis,  and  to  advance  understanding  and  treatment  of 
musculoskeletal disorders through prevention, education and research. The 10 year global initiative 
launched by the UN urges governments around the world to start taking action to draw attention to the 
growing pervasiveness and impact of musculoskeletal diseases and to reduce the social and financial 
burdens to society. Support for this global initiative will raise awareness of musculoskeletal health, 
stimulate research and improve people’s quality of life. 
Musculoskeletal diseases are one of the major causes of disability around the world and have been a 
significant reason for the development of the Bone and Joint Decade [5–8]. Rheumatoid arthritis (RA), 
osteoarthritis (OA), gout and lower back pain are important causes of disability-adjusted-life years in 
both the developed and developing world [9]. 
OA is one of the most common types of arthritis [10–13]. It is a major cause of pain and disability 
in older individuals and is expected to place a heavy burden on healthcare systems around the world as 
the human population ages [14]. The incidence of OA is also expected to increase with the rise in 
obesity and metabolic diseases associated with being overweight [14–17]. It also affects older animals 
and  has  significant  consequences  for  companion  animal  mobility  and  welfare  [18].  OA  is  a Int. J. Mol. Sci. 2012, 13  4204 
 
 
degenerative disease of the whole joint [13] and involves synovial inflammation and the progressive 
and irreversible destruction of the extracellular matrix (ECM) of articular cartilage [10,19,20]. It is also 
characterized by subchondral bone sclerosis, synovial hyperplasia and osteophyte (bony outgrowth) 
formation [21]. OA can occur in any synovial joint but symptomatic OA in humans is most common in 
the knee [16]. Digits of the hand and the hip are also frequently affected. In general weight-bearing 
joints are the worst affected. The main risk factors for OA include age, gender, genetics, obesity, and 
joint injury or instability [17]. Cartilage damage in OA is detected radiographically by decreases in 
joint space width. However, radiographic evidence is seen only after significant cartilage degradation 
has already taken place. 
The major consequence of all forms of arthritis is joint dysfunction, disability, chronic pain, and 
significant  morbidity.  Aside  from  analgesics,  there  are  currently  no  effective  pharmacotherapies 
capable of restoring the structure and function of damaged synovial tissues in any form of arthritis. 
Consequently, there is an acute need for novel drugs and new therapies. In the following section we 
provide  a  brief  overview  of  cartilage  structure  and  function  before  discussing  the  molecular  and 
cellular events that occur in a typical synovial joint in OA. 
2. Articular Cartilage-Structure and Function 
Cartilage is a flexible and mechanically compliant connective tissue found at the end of long bones 
in articulating joints and in the intervertebral disc. It is sub-classified into three different types: elastic 
cartilage, hyaline cartilage and fibrocartilage, which differ in the relative amounts of its three principal 
components, namely collagen fibers, ground substance (proteoglycans) and elastin fibers. Articular or 
hyaline cartilage is a load-bearing tissue with unique biological characteristics (Figure 1).  
Figure 1. Structure of human articular cartilage. This figure illustrates a sample of human 
cartilage from a tissue microarray developed by the Cooperative Human Tissue Network 
(CHTN) [22] of the National Cancer Institute [23]. Cartilage is predominantly an avascular, 
aneural  and  alymphatic  load-bearing  connective  tissue  consisting  of  a  single  cell  type 
known as the chondrocyte. Blood vessels are only present in subchondral bone. 
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Its biochemical properties depend on the structural design of the tissue, the molecular composition 
of the ECM (Figure 2) that makes up the bulk of the tissue volume and the interactions between its 
resident cells and the ECM [24]. 
Figure 2. Molecular composition of the ECM of articular cartilage. The major collagenous 
and non-collagenous components of the territorial and interterritorial cartilage ECM are 
illustrated. 
 
Chondrocytes are the only cells found within the cartilage ECM. Cartilage is avascular, alymphatic 
and aneural. Nutrition is derived from synovial fluid (and for the deep zone by subchondral bone 
vessels). Chondrocytes are architects of cartilage [25], building the macromolecular framework of its 
ECM  from  three  distinct  classes  of  macromolecules:  collagens  (predominantly  type  II  collagens), 
proteoglycans  (mainly  aggrecan),  and  a  variety  of  non-collagenous  proteins  (Figure  2).  Of  the 
collagens present in articular cartilage collagens type II, IX, and XI form a fibrillar meshwork that 
gives cartilage tensile stiffness and strength [24,26,27], whereas collagen type VI forms part of the 
matrix immediately  surrounding  the  chondrocytes,  enabling  them  to  attach  to  the  macromolecular 
framework of the ECM and acting as a transducer of biomechanical and biochemical signals in the 
articular cartilage [28,29]. Large aggregating proteoglycans (aggrecan) are embedded in the collagen 
mesh and  give  cartilage its  stiffness  to  compression, its  resilience and contribute to  its  long-term 
durability [29–32]. Int. J. Mol. Sci. 2012, 13  4206 
 
 
ECM  proteins  in  cartilage  are  of  great  significance  for  the  regulation  of  the  cell  behavior, 
proliferation,  differentiation  and  morphogenesis  [33–41].  Small  proteoglycans,  including  decorin, 
biglycan, and fibromodulin are further embedded in the ECM. Decorin and fibromodulin both interact 
with  the  type  II  collagen  fibrils  in  the  matrix  and  have  roles  in  fibrillogenesis  and  interfibril 
interactions. Biglycan is mainly found in the immediate surrounding of the chondrocytes, where it may 
interact with collagen type VI [24,29]. Modulation of the ECM proteins is regulated by the interaction 
of a diversity of growth factors with chondrocytes [42–46]. In fact, it has been reported recently, that 
IGF-I and TGF-β stimulate the chondrocyte surface expression of integrins, and that this event is 
accompanied by increasing adhesion of chondrocytes to matrix proteins [47]. Other non-collagenous 
proteins in articular cartilage such as cartilage oligomeric matrix protein (COMP) are less well studied 
and may have value as a biomarker of cartilage turnover and degeneration of [48], while tenascin and 
fibronectin influence interactions between the chondrocytes and the ECM [24,49]. The ECM surrounds 
chondrocytes; it protects them from the biomechanical stresses that occur during normal joint motion, 
determines the types and concentrations of molecules that reach the cells and helps to maintain the 
chondrocyte phenotype. 
Throughout life, cartilage is continually remodeled as chondrocytes replace matrix macromolecules 
lost through degradation. Evidence indicates that ECM turnover depends on the ability of chondrocytes 
to detect alterations in the macromolecular composition and organization of the matrix, such as the 
presence of degraded macromolecules, and to respond by synthesizing appropriate types and amounts 
of  new  ECM  components.  It  is  known  that  mechanical  loading  of  cartilage  creates  mechanical, 
electrical, and physicochemical signals that help to direct the synthesizing and degrading activity of 
chondrocytes [50]. In addition, the ECM acts as a signal transducer for chondrocytes [51]. A prolonged 
and severe decrease in the use of the joint leads to alterations in the composition of the ECM and 
eventually  to  a  loss  of  tissue  structure  and  its  specific  biomechanical  properties,  whereas  normal 
physical  strain  stimulates  the  synthesizing  activity  of  chondrocytes  and  possibly  internal  tissue 
remodeling [52,53]. 
Although articular cartilage can tolerate a tremendous amount of intensive and repetitive physical 
stress, it manifests a striking inability to heal even the most minor injury [52,54–56]. This makes joints 
particularly sensitive to degenerative processes [57]. Furthermore, aging leads to alterations in ECM 
composition and alters the activity of chondrocytes, including their ability to respond to a variety of 
stimuli  such  as  growth  factors  [58–60].  All  these  alterations  increase  the  probability  of  cartilage 
degeneration  [55,61–63]  and  emphasize  the  importance  of  interaction  of  chondrocytes  with  their 
surrounding ECM since this interaction regulates their growth, differentiation, and survival [64]. 
3. Articular Cartilage Degradation in OA 
OA (also known as osteoarthrosis or degenerative joint disease) is one of the most prevalent and 
chronic diseases affecting the elderly [65]. The symptoms and signs characteristic of OA in the most 
frequently  affected  joints  are  heat,  swelling,  pain,  stiffness  and  limited  mobility.  OA  is  often  a 
progressive and disabling disease, which occurs in the setting of a variety of risk factors, such as 
advancing age, obesity, and trauma, that conspire to incite a cascade of pathophysiological events 
within  joint  tissues  [66].  Other  sequelae  include  osteophyte  formation  and  synovitis  [13].  These Int. J. Mol. Sci. 2012, 13  4207 
 
 
manifestations are highly variable, depending on joint location and disease severity. Other forms of 
arthritis  include  psoriatic  arthritis,  and  autoimmune  diseases  in  which  the  body’s  immune  system 
attacks itself such as RA. Discussing these diseases in detail is beyond the scope of this review. Figure 
3 outlines the major molecular and cellular changes that occur in the synovial joint in OA. 
Figure 3. Summary of the major molecular and cellular changes that occur in the synovial 
joint  during  inflammation  in  OA.  Summary  of  the  major  synovial,  chondral  and 
subchondral changes observed in OA. This schematic also highlights the actions of various 
white blood cells and inflammatory mediators in OA. Chondral changes include cartilage 
fragmentation  (fibrillation),  cartilage  degradation  and  loss  of  collagen  type  II  and 
glycosaminoglycans,  chondrocyte  apoptosis  (hypocellularity)  and  matrix mineralization. 
Synovial  membrane  changes  in  OA  include  inflammation,  synovial  hypertrophy, 
recruitment and activation of T cells, macrophages and fibroblasts, production of matrix 
metalloproteinases (MMPs) and reactive oxygen species (ROS). Synovial fluid alterations 
in  OA  include  accumulation  of  MMPs  and  ROS,  release  of  IL-1β,  TNF-α  and  other 
proinflammatory cytokines (IL-6, IL-8), release of inflammatory pain mediators such as 
prostaglandin  E2  (PGE2),  formation  of  degradative  products  and  microcrystals. 
Subchondral alterations in OA include subchondral sclerosis (i.e., eburnation), osteoblast 
mediated  subchondral  bone  formation,  proteolysis  (degradation)  of  IGF-I  and  IGF-I 
binding proteins, increased production of some growth factors and cytokines including: 
transforming growth factor β, TGF-β, PGE2; interleukin 6, IL-6 and IGF-I. 
 
OA can affect any synovial joint but it primarily affects large load-bearing joints such as the hip and 
knee. The disease is essentially one acquired from daily wear and tear of the joint. Its most prominent Int. J. Mol. Sci. 2012, 13  4208 
 
 
feature is the progressive destruction of articular cartilage [11]. OA begins in articular cartilage and 
eventually spreads to other synovial tissues. The current consensus is that OA is a disease involving 
not only articular cartilage but also the synovial membrane, subchondral bone and peri-articular soft 
tissues [67]. OA may occur following traumatic injury to the joint, subsequent to an infection of the 
joint or simply as a result of aging and the mechanical stresses associated with daily life. 
It is now generally accepted that OA must be viewed not only as the final common pathway for 
aging  and  injuries  of  the  joint,  but  also  as  an  active  and  inflammatory  joint  disease.  As  medical 
advances  lengthen  average  life  expectancy,  OA  will  become  an  even  larger  public  health  
problem—not only because it is a manifestation of aging but because it usually takes many years to 
reach  clinical  relevance.  OA  is  already  one  of  the  ten  most  disabling  diseases  in  industrialized 
countries. It is one of the most prevalent and chronic diseases affecting the elderly [65]. OA is rare in 
people under 40 but becomes more common with age—most people over 65 years of age show some 
radiographic evidence of OA in at least one or more joints. OA is the most frequent cause of physical 
disability  among  older  adults  globally.  According  to  the  National  Institute  of  Arthritis  and 
Musculoskeletal  and  Skin  Diseases  (NIAMS)  more  than  20  million  Americans  are  estimated  to  
have OA [68]. It is also anticipated that by the year 2030, 20% of adults will have developed OA in 
Western Europe and North America. Statistical data from epidemiological studies in North America 
and Australia suggest that arthritis is the number one condition associated with functional limitation 
and physical disability among US population aged 65 and older and affects 30% of the population [69]. 
The data from the 2003 Survey of Disability, Ageing and Carers in Australia [70] suggests that the 
percentage of older people with OA is even higher—around 50% profoundly and severely effecting 
their core activity and limiting their mobility. The reported prevalence of arthritis and its associated 
risk factors (i.e., obesity and metabolic disease) has also increased among people aged 65 and over in 
nearly all European member states. 
The  symptoms  and  signs  characteristic  of  OA  in  the  most  frequently  affected  joints  are  heat, 
swelling, pain, stiffness and limited mobility. OA is often a progressive and disabling disease, which 
occurs in the setting of a variety of risk factors, such as advancing age, obesity, and trauma, that 
conspire to incite a cascade of pathophysiological events within joint tissues [66]. Other important 
sequelae include osteophyte formation, inflammation of the synovial membrane (synovitis) and joint 
swelling  [13].  These  manifestations  are  highly  variable,  depending  on  joint  location  and  disease 
severity. Other forms of arthritis include psoriatic arthritis, and autoimmune diseases in which the 
body’s immune system attacks itself such as RA. The synovitis that occurs in both the early and late 
phases of OA is associated with alterations in the adjacent cartilage. Catabolic and proinflammatory 
mediators such as cytokines, nitric oxide, prostaglandin E2 (PGE2) and neuropeptides are produced by 
the inflamed synovium and alter the balance of cartilage matrix degradation and repair, leading to 
excess  production  of  the  proteolytic  enzymes  responsible  for  cartilage  breakdown  [71].  Cartilage 
alterations induce further synovial inflammation, creating a vicious circle and the progressing synovitis 
exacerbates clinical symptoms and stimulates further joint degradation in OA [71]. Figure 3 outlines 
the major molecular and cellular changes that occur in the synovial joint in arthritis and synovitis. 
OA, is an important cause of disability-adjusted-life years in both the developed and developing 
world [9]. Until recently OA was viewed as a ―degenerative‖ or ―wear-and-tear‖ disease and held little 
interest for most clinicians. It is now accepted that the age-related degeneration of articular cartilage as Int. J. Mol. Sci. 2012, 13  4209 
 
 
part of the clinical syndrome of OA is one of the most common causes of pain and disability in middle-
aged and older people [9]. OA is the most common form of joint disease, with the majority of the 
population over 65 years of age demonstrating radiographic evidence of OA in at least one joint.  
4. Cytokines and OA 
Cytokines are signaling molecules and major mediators of inflammatory responses. They are small 
proteins and signaling molecules produced by a variety of different cell types. They control many 
different  cellular functions including proliferation, differentiation and cell survival/apoptosis. They 
play  essential  an  indispensable  roles  in  cell  signaling  and  communication  and  possess  potent 
immunomodulatory properties. They are also involved in a plethora of pathophysiological processes 
including viral infections, autoimmune diseases, arthritis and cancer. Cytokines are synthesized under 
various stimuli by a variety of cells of both the innate (monocytes, macrophages, dendritic cells) and 
adaptive (T- and B-cells) immune systems. They have been classed as lymphokines, interleukins, and 
chemokines, based on their functions. The term ―interleukin‖ was initially used by researchers for 
those cytokines whose presumed targets are principally leukocytes. The term ―chemokine‖ refers to a 
specific  class  of  cytokines  that  mediates  chemo-attraction  (chemotaxis)  between  cells.  In  many 
publications cytokines are listed along with hematopoietic growth factors, interferons, lymphokines, 
monokines,  chemokines,  and  other  cytokines  [72].  Cytokines  can  be  classified  into  two  groups: 
proinflammatory and anti-inflammatory. Proinflammatory cytokines, including IFN-γ, IL-1β, IL-6 and 
TNF-α, are predominantly derived from the innate immune cells and Th1 cells. Anti-inflammatory 
cytokines, including IL-10, IL-4, IL-13 and IL-5, are synthesized from Th2 immune cells. The role of 
proinflammatory cytokines in RA is very well established [73]. Anti-cytokine therapy for RA has 
become  a  clinical  treatment  for  aggressive  forms  of  the  disease  [74].  However,  proinflammatory 
cytokines also contribute to the pathogenesis of OA. The disease is strongly linked to aging; cell stress, 
injury or damage in response to chronic inflammation and exposure to cytokines, chemokines, and 
proteases is thought to drive its progression [75]. 
5. The Role of Cytokines in Arthritis 
It is now generally accepted that proinflammatory cytokines are pleiotropic contributors to synovial 
joint pathology in OA and RA. In the following sections we discuss the principal cytokines involved in 
the  pathogenesis  of  OA  and  its  progression.  Many  studies  have  demonstrated  the  involvement  of 
cytokines in the pathogenesis of OA (Figure 3). They are involved with synovial membrane, cartilage 
and bone changes in the disease process. It is now thought that much of the cytokine expression is 
initially  by  the  synovium,  predominantly  from  the  synovial  macrophages,  which  drive  the 
inflammatory and destructive responses in OA [76]. These cytokines are thought to diffuse through the 
synovial fluid into the cartilage where they stimulate the chondrocytes and synoviocytes to synthesize 
further  cytokines  as  well  as  degradative  proteases.  The  intimal  cells  of  the  synovium  are  most 
significant in the production of cytokines that cause inflammation [77]. The main proinflammatory 
cytokines thought to be involved in the pathogenesis of OA are Tumor Necrosis Factor α (TNF-α) and 
Interleukin-1 β (IL-1β) which act on synoviocytes and chondrocytes through specific interactions with 
cytokine  receptors  on  the  cell  surface.  The  receptors  thought  to  be  involved  in  OA  are  the  Int. J. Mol. Sci. 2012, 13  4210 
 
 
IL-1β receptor, IL-1R type I, and the TNF-α receptor, TNF-R55, due to their elevated expression in 
OA human synovial fibroblasts [78,79]. 
There are also other proinflammatory cytokines produced by the synovium and involved in the OA 
disease process to a lesser extent. The effects of the proinflammatory cytokines on cartilage are shown 
in Table 1. 
Table 1. Proinflammatory cytokines involved in OA. 
Cytokine  Expression   Functions  References 
TNF-α  Synoviocytes 
Chondrocytes 
Increase cartilage degradation and bone 
resorption 
 [80,81] 
Inhibit glycoprotein and collagen synthesis.   [82] 
Upregulate MMP expression   [83] 
Stimulate other cells to produce 
proinflammatory cytokines and growth 
factors 
 [84] 
Stimulate proangiogenic factor release   [85] 
Stimulate other cells to produce chemotactic 
cytokines 
 [86,87] 
Stimulate Nitric Oxide (NO) production   [88] 
Induce chondrocyte apoptosis   [89] 
IL-1β  Synoviocytes 
Chondrocytes 
Macrophages 
Increase cartilage degradation and bone 
resorption 
 [80,81,90] 
Inhibit proteoglycan synthesis   [91,92] 
Upregulate MMP expression   [93] 
Production of proteolytic enzymes    [94] 
Stimulate other cells to produce 
proinflammatory cytokines 
 [77] 
Stimulate other cells to produce chemotactic 
cytokines 
 [86,87] 
Stimulate proangiogenic factor release   [85] 
Stimulate NO production   [95] 
Induce chondrocyte apoptosis   [89] 
IL-6 
 
Synoviocytes 
Chondrocytes  
osteoblasts 
 
Inhibit proteoglycan synthesis    [96] 
Reduce chondrocyte proliferation   [96] 
Increase MMP-2 activity   [97] 
Increase aggrecanase-mediated proteoglycan 
catabolism 
 [98] Int. J. Mol. Sci. 2012, 13  4211 
 
 
Table 1. Cont. 
Cytokine  Expression   Functions  References 
IL-8  Monocytes 
Synoviocytes 
Chondrocytes 
Osteoblasts  
Recruits leucocytes   [99] 
Neutrophil chemoattractant   [100] 
Stimulates release of proinflammatory 
cytokines 
 [101] 
Hypertrophic differentiation and calcification 
of chondrocytes 
 [102] 
IL-17  Activated  
T-lymphocytes 
Induce NO synthesis   [103,104] 
Induce MMP synthesis   [103,104] 
Increase production of IL-1β, Il-6 and IL-8   [103,105] 
Stimulate release of proangiogenic factors   [106] 
IL-18  Macrophages 
Synovial fibroblasts 
 
Stimulate release of proinflammatory 
cytokines 
 [107,108] 
Stimulate angiogenesis   [109] 
Induce NO synthesis   [108] 
Synovial hyperplasia and inflammatory cell 
recruitment 
 [110] 
Induce chondrocyte apoptosis   [111] 
Reduce expression of cartilage matrix 
components 
 [111] 
Up-regulate fibronectin- a mediator of 
cartilage destruction 
 [111] 
Leukaemia 
Inhibitory 
Factor 
(LIF) 
Synovial fibroblasts 
Chondrocytes 
Stimulate proinflammatory cytokine 
expression 
 [112,113] 
Increase pro-MMP-2 synthesis   [97] 
Increase MMP-13 synthesis and activity   [114] 
Increase cartilage resorption   [115] 
Decrease proteoglycan synthesis   [116] 
Leukocyte infiltration into synovial fluid   [117] 
Increase cartilage degradation when in 
combination with IL-1β and TNF-α 
 [115] 
6. NF-κB Signaling in Arthritis 
The activation of NF-κB (nuclear factor-κB) transduction pathway has been linked with a variety of 
inflammatory  diseases,  including  cancer,  atherosclerosis,  myocardial  infarction,  diabetes,  allergy, 
asthma,  arthritis,  Crohn’s  disease,  multiple  sclerosis,  Alzheimer's  disease,  osteoporosis,  psoriasis, 
septic  shock,  and  AIDS  [118,119].  As  an  activator  of  many  pro-inflammatory  cytokines  and 
inflammatory processes NF-κB is a principal target to alleviate the symptoms of such inflammatory 
diseases [120]. NF-κB is a rapidly acting primary transcription factor found in all cell types. It is 
involved in cellular responses to proinflammatory stimuli such as cytokines and stress and plays a key 
role in regulating the immune response to infection. NF-κB can be triggered by a host of stress-related 
stimuli  including  proinflammatory  cytokines,  excessive  mechanical  stress  and  ECM  degradation 
products [121]. In unstimulated cells NF-κB dimers are sequestered inactively in the cytoplasm by a Int. J. Mol. Sci. 2012, 13  4212 
 
 
protein  complex  called  inhibitor  of  κB  (IκB).  IκB  inactivates  NF-κB  by  masking  the  nuclear 
localization  signals  (NLS).  Activation  of  NF-κB  occurs  via  degradation  of  IκB,  a  process  that  is 
initiated by its phosphorylation by IκB kinase (IKK). Phosphorylated IκB becomes dissociated from 
NF-κB, unmasking the NLS. Phosphorylation also results in IκB ubiquitination and targeting to the 
proteasome.  NF-κB  can  now  enter  the  nucleus  and  regulate  gene  expression.  NF-κB  turns  on 
expression  of  IκB  forming  a  negative  feedback  loop.  Targeted  strategies  to  prevent  unwanted  or 
excessive NF-κB activation are the focus of current research. Work in this area is focused on the use of 
highly specific drug modalities, siRNAs or other biological inhibitors [121]. Further work is needed to 
evaluate the effects of efficacious, targeted NF-κB inhibitors in animal models of OA disease in vivo 
and  to  also  target  these  strategies  only  to  affected  cartilage  and  joints  to  avoid  other  undesirable 
systemic effects [121]. 
Recent research has shown that the pathway that activates NF-κB can be interrupted or functionally 
modulated by naturally occurring phytochemicals derived from spices such as curcumin, capsaicin, 
eugenol, gingerol, anethol, ursolic acid, diallyl sulfide, S-allylmercaptocysteine, ajoene, and ellagic 
acid [118]. 
7. Curcumin and Resveratrol—Naturally Occurring NF-κB Inhibitors 
Current treatments for OA and gut are associated with unwanted side effects and are expensive. 
Natural products do not have such disadvantages, offer alternative treatment options for OA [122,123]. 
Traditional and complementary medicine is  known to  be fertile  ground for the source of modern 
medicines [124]. In many different chronic diseases (including OA) in which inflammation is known 
to play a central role, plant derived phytochemicals (i.e., curcumin and resveratrol) have been shown to 
exhibit  therapeutic  potential.  The  main  aim  of  OA  therapy  is  to  counteract  the  local  chronic 
inflammation, associated inflammatory symptoms in the joints, delay joint degradation, reduce and 
minimize  disability  and  provide  a  better  quality  of  life  for  patients.  It  is  recognized  that  current 
treatments  for  arthritis  are  inefficient,  cause  substantial  side  effects,  and  tend  to  be  expensive 
(especially when the is cost of treatment is calculated and spread over the long time course of the 
disease).  However,  natural  products  do  not  have  such  disadvantages  and  offer  novel  and 
complementary  treatment  opportunities  [122,123].  A  number  of  natural  substances  have  been 
investigated  for  their  anti-inflammatory  capabilities,  including  omega-3  fatty  acids  (FA)  [125],  
curcumin  [126],  resveratrol  [127],  the  polyphenolic  green  tea  catechins  [128,129],  and  various 
flavonoids [130,131]. Many of them have the ability to interfere with inflammatory processes and their 
mediators. Thus their use along with NSAIDs may reduce inflammation and damage to joint tissues 
and could be of prophylactic and therapeutic value. Therefore, naturally occurring compounds capable 
of blocking NF-κB mediated catabolic activity may prove to be promising therapeutic agents for the 
treatment of OA and other inflammatory conditions. This realization has resulted in the proliferation of 
new research aimed at understanding how nutrients and genes interact. This new field is known as 
nutrigenomics  and  this  paper’s  focus  on  curcumin  and  resveratrol  and  many  other  studies  in  the 
literature highlight how these compounds target transcription factors such as NF-κB, AP-1, Egr-1, 
STATs,  PPAR-γ,  β-catenin,  nrf2,  EpRE,  p53,  CBP,  and  androgen  receptor  (AR)  and  AR-related 
cofactors [132]. Int. J. Mol. Sci. 2012, 13  4213 
 
 
8. Curcumin 
Curcuma longa or turmeric is a tropical plant native to south and southeast tropical Asia. It is a 
member of the ginger family (Zingiberaceae) and is one of the most important of the Indian spices. 
Curcumin (diferuloyl methane) is the principal curcuminoid and the most active component in turmeric. 
It  may  make  up  2–5%  of  the  total  spice  in  turmeric.  Commercial  curcumin  contains  three  major 
components: diferuloylmethane (82%), demethoxycurcumin (15%) and bisdemethoxycurcumin (3%), 
together referred to as curcuminoids [133], all of which have anti-inflammatory activity. Turmeric has 
been used in Ayurvedic Medicine (traditional Indian medicine) for thousands of years to treat various 
common diseases including gastrointestinal diseases (i.e., stomach ulcers), jaundice, arthritis, wounds 
and skin and eye infections [134–136]. Preclinical and clinical studies have shown that curcumin has 
potential  therapeutic  value  against  most  chronic  diseases  including  neoplastic,  neurological, 
cardiovascular, pulmonary, metabolic and arthritic diseases. Several recent studies have also shown 
that curcumin has potential for the complementary treatment of arthritis [137,138]. 
The  first  preliminary  study  on  the  anti-rheumatic  activity  of  curcumin  was  published  in  1980. 
Unfortunately, this study was fundamentally flawed because of the lack of appropriate controls [139]. 
Studies in a rat model of joint inflammation showed that oral administration of capsaicin and curcumin 
lowered the levels of paw inflammation [140]. In early 2000 work on synovial fibroblasts derived from 
RA patients showed that curcumin inhibits the macrophage migration inhibitory factor (MIF) induced 
up-regulation  of  matrix  metalloproteinases  MMP-1  (interstitial  collagenase)  and  MMP-3  
(stromelysin) [141]. Curcumin strongly inhibits collagenase and stromelysin expression at micromolar 
concentrations  [142]. Curcumin is  actually  a potent inhibitor of MIF  [143]. Curcumin is  a potent 
inhibitor of the production of inflammatory and catabolic mediators by chondrocytes, suggesting that 
this natural compound could be efficient in the treatment of OA [144]. Curcumin can induce apoptosis 
and  inhibit  prostaglandin  E(2)  (PGE2)  production  in  synovial  fibroblasts  of  patients  with  RA, 
suggesting that curcumin might be used to control hyperplasia of the synovial fibroblasts in RA [145].  
In  chondrocytes  curcumin  was  shown  to  suppress  oncostatin  M  (OSM)  stimulated  STAT1 
phosphorylation, DNA-binding activity of STAT1, and c-Jun N-terminal kinase activation as well as 
inhibiting OSM-induced MMP-1, MMP-3, MMP-13, and TIMP-3 gene expression [146]. Curcumin 
was  also  shown  to  induce  a  48–99%  suppression  of  MMP-3  and  45–97%  downregulation  of  
MMP-13  in  human  chondrocytes  and  8–100%  (MMP-3)  and  32–100%  (MMP-13)  in  bovine 
chondrocytes [147]. Curcumin was also shown to suppress TNF-α-induced MMP-13 expression in 
primary chondrocytes and SW1353 chondrosarcoma cells [135]. 
Work from our laboratories has demonstrated some of the protective and anti-inflammatory effects 
of curcumin using biochemical and morphological techniques. To test the hypothesis that curcumin 
protects chondrocytes from morphological alterations induced by IL-1β, we investigated its in vitro 
effects  on  apoptotic  signaling  proteins  and  key  cartilage-specific  matrix  components  in  
IL-1β-stimulated chondrocytes. Transmission electron microscopy was employed to demonstrate that 
curcumin  inhibits  the  early  degenerative  changes  induced  by  IL-1β  [148].  Additionally,  curcumin 
antagonized the suppression of collagen type II and β1-integrin synthesis and caspase-3 activation 
induced by IL-1β was inhibited by curcumin [148]. This study clearly demonstrated that curcumin 
exerts anti-apoptotic and anti-catabolic effects on IL-1β-stimulated articular chondrocytes and may Int. J. Mol. Sci. 2012, 13  4214 
 
 
have novel therapeutic potential for treating OA and related osteoarticular diseases [148]. We used an 
explant model of cartilage inflammation to  demonstrate that  IL-1β-induced  ECM degradation and 
glycosaminoglycan release can be inhibited by curcumin [13]. 
Curcumin  appears  to  exert  its  anti-inflammatory  effects  in  a  ―concentration-dependent‖  or  
―dose-dependent‖  manner.  Studies  on  RA-derived  synovial  fibroblasts  have  shown  that  curcumin  
dose-dependently abrogates the effect of IL-18 on VEGF production [149]. Interestingly, a study on 
biological activities of turmeric extract has shown that the three major curcuminoids in turmeric are 
responsible for its anti-arthritic effects while the remaining compounds in crude turmeric extracts may 
actually inhibit its anti-inflammatory and protective effects [150]. Studies on other curcuma plants 
have  shown  that  there  is  a  possible  curcuminoid-independent  pathway  mediated  by  
curcuma phaeocaulis extract [151]. Further studies are required to corroborate these findings. 
Treatment  of  chondrocytes  with  curcumin  suppresses  IL-1β-induced  NF-κB  activation  via 
inhibition  of  IκBα  phosphorylation,  IκBα  degradation,  p65  phosphorylation  and  p65  nuclear 
translocation [152]. Curcumin also inhibits the IL-1β-induced stimulation of up-stream protein kinase 
B  Akt,  molecular  events  that  correlate  with  down-regulation  of  NF-κB  targets  including  COX-2  
and MMP-9 [152]. 
Curcumin is also able to antagonize the IL-1β and TNF-α-dependent up-regulation of MMPs and 
COX-2. Curcumin has  been shown to  inhibit the inflammatory and apoptotic effects  of  IL-1β  on 
chondrocytes and this correlates with down-regulation of NF-κB-specific gene products that are known 
to  mediate  inflammation,  degradation  and  apoptosis  of  chondrocytes  in  OA.  Additionally,  both 
curcumin  suppressed  IL-1β-induced  down  regulation  of  the  cartilage  specific  ECM  component 
collagen type II and of the cartilage specific master transcription factor Sox-9. Furthermore, inhibition 
of NF-κB activation by curcumin occurs mainly through the IKK inhibition [135,138,141,152]. 
When considering the biological effects of curcumin in cartilage and synovial cells and joint tissues, 
the overriding question is whether curcumin is safe. The research conducted to date with curcumin 
suggests that it has a good safety record. However, this is not supported by clinical evidence and data 
from clinical trials. Another important and largely neglected issue is the bioavailability of curcumin 
and curcuminoids, which is poor generally. Enhancing the bioavailability of curcumin is an important 
and goal and is likely to bring this promising natural product to the forefront of therapeutic agents for 
treatment of human diseases [153]. Curcumin is also a powerful inhibitor of inflammatory pathways 
and mediators. The schematic shown in Figure 4 summarizes the available information in PubMed on 
the effects of curcumin on the TNF-α receptor and its downstream signaling pathway.  Int. J. Mol. Sci. 2012, 13  4215 
 
 
Figure 4. Schematic of the effects of curcumin on the TNF-α receptor and its downstream 
signaling pathway. The biochemical pathway illustrated here was generated by text mining 
and makes  use of  a collection of canonical  Ariadne pathways  in  addition  to  MedScan  
text mining. 
 
Its  anti-catabolic  effects,  namely  reducing  degradative  enzyme  expression  and  activity,  and  its 
positive  influence  on  anabolic  gene  expression  suggests  that  it  may  be  a  suitable  adjunct  to 
conventional pharmaceutical (i.e., NSAID) therapy. The available information suggests that curcumin 
could  be an alternative  to  NSAIDs.  In contrast to  NSAIDs, curcumin  has  no gastrointestinal  side 
effects,  and  can  even  protect  the  gastric  mucosa.  Therefore,  curcumin  could  be  beneficial  in  the 
management  of  chronic  inflammatory-related  joint  disease,  including  OA.  However,  despite  this 
optimistic view, it must be recognized that there is still a paucity of data regarding possible adverse 
effects of curcumin at concentrations that are biologically effective in vitro. Indeed, the absence of 
systemic  adverse  effects  after  oral  administration  of  curcumin  is  probably  the  result  of  its  poor 
bioavailability and chemical modification by the gut and liver. Whilst some evidence exists for toxicity, 
at  super-physiological  concentrations,  these  are  unlikely  to  be  experienced  or  achieved  in  vivo. 
Nevertheless, we cannot exclude the possibility that increasing curcumin absorption, by chemical or 
natural process, could have unsuspected deleterious effects. It is now documented that curcumin at 
concentrations in excess of 50 mM shows cytotoxicity in a chondrocyte cell line [154]. The relevance 
of  this  toxicity  in  in  vitro  models  is  highly  questionable.  Nevertheless,  the  long-term  effects  of 
curcumin have not been studied and there is no published information about the possible side effects of 
the metabolites of curcumin. Further work is therefore required to address the issues of bioavailability 
and tissue accumulation in order to calculate appropriate dose formulations to assess whether curcumin Int. J. Mol. Sci. 2012, 13  4216 
 
 
can be convincingly considered as an aid to treating OA. Curcumin regulates inflammatory cytokines 
such as IL-1β, IL-6, IL-12, TNF-α and IFN-γ and associated JAK-STAT, AP-1, and NF-κB signaling 
pathways in immune and connective tissue cells [155]. 
9. Clinical Trials of Curcumin 
There  are  currently  no  registered  clinical  trials  of  curcumin  in  OA.  ―Curcumin  in  Rheumatoid 
Arthritis‖ (ClinicalTrials.gov [156] Identifier: NCT00752154 [157]) is a clinical trial registered on the 
Clinical Trials database. The study is sponsored by University of California at Los Angeles. It is a 
randomized, placebo-controlled crossover study in which 40 subjects will receive a total of 4 g of 
curcumin  per  day  (capsule  form,  precise  composition  not  disclosed)  and  then  switch  to  placebo.  
The subjects’ participation may last up to 8 months. By completion of the study, all 40 subjects will 
have  taken  curcumin  and  placebo  for  4  months  each.  Subjects  will  have  blood  tests,  complete 
questionnaires, and be seen by the study doctor. At the present time status of this study is unknown and 
it looks like the original completion deadline will not be met. However, when the study is completed it 
will be very interesting to see if curcumin has provided any benefits for RA patients. 
10. Bioavailability and Topical Delivery of Curcumin 
The major problem associated with the use of curcumin as a drug is its low bioavailability. A recent 
study has attempted to enhance the bioavailability of curcumin by complexation with phosphatidyl 
choline  followed  by  pharmacokinetic  studies  in  rats  [158].  The  complex  was  shown  to  have 
significantly  increased  absorption  compared  with  curcumin,  when  given  in  equimolar  doses.  The 
complex  also  showed  enhanced  bioavailability,  improved  pharmacokinetics,  and  increased 
hepatoprotective  activity  as  compared  with  curcumin  [158].  The  authors  have  proposed  that  the 
enhanced bioavailability of the complex may be due to its amphiphilic nature, which greatly enhance 
the water and lipid solubility of the curcumin. This study opens up new opportunities for enhancing the 
absorption and bioavailability, and pharmacokinetics of curcumin. Several companies have already 
started selling products combining curcumin with phosphatidyl choline for improved absorption. 
Another area of interest is  enhancing the topical  delivery of  curcumin  [159]. This  approach is 
intended  to  increase  the  absorption  of  curcumin  through  skin.  Combinations  of  cyclodextrins  and 
alginates  were  used  in  a  study  by  Hegge  and  colleagues  to  solubilize  curcumin  in  aqueous  
vehicles  intended  for  topical  delivery  [160].  The  study  concluded  that  a  combination  of  
hydroxypropyl-β-cyclodextrin and propylene glycol alginate enhances curcumin solubility and release 
from the vehicle [160]. These studies have demonstrated the importance of optimizing the solvent 
systems when utilizing cyclodextrins as drug carriers for topical treatments [159,160]. 
11. Synergistic Effects of Curcumin and NSAIDs 
There is increasing interest in using curcumin in conjunction with NSAIDs to reduce the dosage of 
NSAIDs. Banerjee  et  al., (2003) used an adjuvant  model of rat  inflammation to  demonstrate that 
curcumin and ibuprofen modulate inflammatory biomarkers such as C-reactive protein when used in 
combination  [161].  Curcumin  synergistically  potentiates  the  growth-inhibitory  and  pro-apoptotic Int. J. Mol. Sci. 2012, 13  4217 
 
 
effects of the NSAID celecoxib in OA-derived synovial adherent cells [162]. This was one of the first 
studies to show that synergistic effects of curcumin and celecoxib may enable the use of celecoxib at 
lower and safer concentrations [162]. Evaluation of the effects of celecoxib and curcumin in patients 
with OA is ongoing in human clinical trials [163]. Synergistic action of curcumin and conventional 
NSAIDs is an interesting concept and may pave the way for a novel combination treatment in OA and 
other rheumatologic disorders [162]. Ongoing clinical trials should provide a deeper understanding of 
the mechanisms and therapeutic potential of curcumin [164]. 
12. Resveratrol 
Resveratrol or trans-3,5,4'-trihydroxystibene is a polyphenolic, antifungal natural phytoalexin found 
in grapevines (Vitis vinifera) and a variety of other plants. It is found in the vines, roots, seeds and 
stalks, but its highest concentration is in grape skins. Resveratrol has been shown to possess potent 
anti-inflammatory,  antioxidant  and  anticancer  properties.  It  has  been  studied  because  of  its  
anti-carcinogenic,  anti-inflammatory  and  cardioprotective  properties  (coronary  artery  protection 
cumulating in the so called ―French Paradox‖) [165]. In addition resveratrol is thought to as suppresses 
angiogenesis  and  prevent  diabetes  mellitus.  There  are  also  suggestions  that  it  may  prolong  
lifespan [166–168]. Since resveratrol is a potent and specific inhibitor of cytokine-induced NF-κB 
activation, it may have potential for treating OA [137,138,143,169,170]. 
Studies  in  the  rat  suggest  that  resveratrol  is  absorbed  in  the  duodenum.  However,  
resveratrol-glucuronide  was  the  major  form  absorbed  when  compared  to  the  minute  amounts  of 
unconjugated  resveratrol  and  resveratrol-sulfate  [171].  Resveratrol  is  glucuronated  in  the  liver  
and  sulfated  in  both  the  liver  and  the  duodenum  [172].  The  major  derivatives  of  resveratrol 
glucuronidation  are  trans-resveratrol-3-O-glucuronide,  trans-resveratrol-4'-O-glucuronide,  and  
trans-resveratrol-3-O-sulfate [173]. Therefore, resveratrol exhibits numerous different mechanisms of 
action and targets are great number of intracellular molecules.  
13. Resveratrol and Transcription factor NF-κB 
As  discussed  earlier  many  inflammatory  factors  involved  in  arthritis,  are  regulated  by  the 
transcription  factor  Nuclear  Factor-κB  (NF-κB)  [174].  NF-κB  regulates  many  important  signaling 
pathways in diseases with an inflammatory component [175–177]. Resveratrol blocks TNF-α-induced 
activation of NF-κB and suppresses TNF-α-induced phosphorylation and nuclear translocation of the 
p65 subunit of NF-κB and NF-κB-dependent reporter gene transcription [178]. 
Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenases. Lipoxygenases are 
dioxygenases  with  peroxidase  activity  involved  in  the  synthesis  of  mediators  for  inflammatory, 
atherosclerotic, and carcinogenic processes. Additionally resveratrol can inhibit lipoxygenases through 
being oxidized by their peroxidase activity. Resveratrol and its oxidized form can act as inhibitors of 
the dioxygenase activity of lipoxygenase [179]. Int. J. Mol. Sci. 2012, 13  4218 
 
 
14. Resveratrol and OA 
The phenomena that inflammatory cytokines such as IL-1β and TNF-α stimulate matrix degrading 
enzymes  such  as  matrix  metalloproteinases  (MMPs)  and  cyclooxygenase-2  (COX-2),  through 
activation of NF-κB, leading to cartilage matrix destruction, joint inflammation and play an important 
part  in  pathogenesis  of  RA  and  OA  [152].  COX-2  activation  stimulates  prostaglandin  production 
mediating  inflammation  [180].  The  classical  treatment  for  OA  and  RA  is  with  COX  inhibitors. 
However, NSAIDs have well known and severe side effects such as gastric ulcerations and do not 
inhibit the production of inflammatory stimulating mediators. Thus, degradation of joint cartilage is 
further promoted. This is why there is an emerged request for anti-inflammatory treatment that on one 
hand inhibits COX-2 (and thus  prostaglandin production) but  on the other hand further block the 
continuing joint  degeneration.  Interestingly, Subbaramaiah and co-workers have demonstrated that 
resveratrol has COX-2 inhibitory effects. The addition of pure resveratrol inhibited COX-2 expression 
and the production of prostaglandin E2 [181]. Furthermore, Elmali et al. demonstrated that intra-articular 
injections of resveratrol in rabbit inflammatory arthritis model had a chondroprotective effect on the 
cartilage [169,182]. We have shown that resveratrol has anti-apoptotic effects on primary chondrocytes 
by inhibiting the IL-1β-induced stimulation of caspase-3 and the cleavage of the DNA repair enzyme 
poly(ADP-ribose)polymerase (PARP) in human articular chondrocytes [183]. Furthermore, we have 
demonstrated that resveratrol inhibits the cysteine protease caspase-3 and the subsequent cleavage of 
the DNA repair enzyme PARP and the IL-1β-induced up-regulation of reactive oxygen species (ROS) 
in chondrocytes [137].  
In  vitro  studies  have  shown  that  IL-1β-induced  suppression  of  chondrocyte  proliferation  and 
morphological alterations are suppressed by resveratrol. Resveratrol inhibits membrane-bound IL-1β 
and mature IL-1β protein production in chondrocytes. Furthermore, co-treatment of IL-1β-stimulated 
cells with resveratrol blocks activation of caspase-3, PARP cleavage, apoptosis and accumulation of 
tumor suppressor gene protein p53 and induces ubiquitin-independent degradation of p53. Resveratrol 
suppresses  IL-1β-induced,  NF-κB-dependent  proinflammatory  and  matrix  degrading  gene  products 
including MMPs, caspase-3, VEGF and COX-2. Resveratrol inhibits IL-1β-induced IκB-α degradation 
and  consequently  accumulated  IL-1β-induced  IkB-α  phosphorylation.  Resveratrol  suppressed  
IL-1β-induced NF-κB dependent expression of apoptosis-related gene products by the accumulation of 
phosphorylated IκB-α, ubiquitinated IκB-α and inhibition of proteasome activity [137,138,183,184]. 
The in vivo effects of intra-articular injections of resveratrol on cartilage and synovium have been 
studied in a rabbit model of OA [169]. Resveratrol reduces cartilage tissue destruction and may protect 
cartilage against the development of experimentally induced OA. 
There is increasing evidence to show that resveratrol may act on the sirtuin system. The silent 
information regulator (SIR) genes (sirtuins) comprise a highly conserved family of proteins. SirT1, the 
first member of the sirtuin family, is an enzyme that deacetylates proteins that contribute to cellular 
regulation (reaction to stressors, longevity). Two recent review articles have examined the published 
research on resveratrol’s effects on the expression and function of sirtuins [185]. These papers also 
discuss the dietary, lifestyle, and environmental factors that influence sirtuin activity, especially dietary 
activators like resveratrol. Int. J. Mol. Sci. 2012, 13  4219 
 
 
15. Clinical Trials of Other Phytochemical Based Products Approved as Medical Foods 
Limbrel [186] is a prescription medical food product for the clinical dietary management of the 
metabolic processes of osteoarthritis (OA). Limbrel was developed and formulated specifically for 
patients with OA. Although it is not a NSAID, nor a COX-2 selective inhibitor, it is proposed to 
function  as  an  anti-oxidant  as  well  as  being  a  dual  inhibitor  of  the  cyclooxygenase  (COX)  and 
lipoxygenase (LOX) enzymes of arachidonic acid metabolism. Limbrel is manufactured according to 
FDA (Food and Drug  Administration) current  Good Manufacturing Practices (cGMP).  It  contains 
flavocoxid,  a  proprietary  blend  of  natural  ingredients  from  phytochemical  food  source  materials. 
Flavocoxid is comprised primarily of the flavonoids such as baicalin and catechin. These or similar 
ingredients can be found in common foods such as soy, peanuts, cauliflower, kale, apples, apricots, 
cocoa and green tea. The fact that these and similar ingredients have been widely researched and used 
in medicinal products in other countries also supports biacalin and catechin’s safety and effectiveness. 
Limbrel provides levels of these flavonoids needed to meet the distinctive nutritional requirements of 
people  with  osteoarthritis  and  cannot  be  obtained  through  simply  changing  the  diet.  A  recently 
conducted  clinical  trial  of  Limbrel  (ClinicalTrials.gov  [156]  Identifier:  NCT00928837)  [187]  has 
shown Limbrel to be effective in safely managing the unique nutritional needs of OA with side effects 
comparable to placebo. The Primary and Secondary Outcome Measures were to compare the efficacy, 
safety, quality of life and economic impact of Limbrel compared to the NSAID Naproxen and placebo. 
16. Concluding Remarks 
Nutrigenomics is an exciting area of research that holds much promise for the development of novel 
therapeutic  strategies  for  the  treatment  of  inflammatory  diseases.  However,  wider  acceptance  of 
nutritional  intervention,  dietary  supplements  and  nutraceuticals  by  medical  practitioners  arthritis 
patients and the scientific research community will require multi-disciplinary approaches that combine 
original hypothesis driven research with well-designed basic, clinical and epidemiological studies. The 
published data supporting the anti-inflammatory and anti-catabolic effects of curcumin and resveratrol 
and their synergistic activity is quite robust. Recent work has shown that curcumin and resveratrol 
protect chondrocytes from the catabolic actions of IL-1β including MMP-3 up-regulation, inhibition of 
collagen  type  II  and  down-regulation  of  β1-integrin  expression.  These  phytochemicals  can  blocks  
IL-1β-induced proteoglycan degradation, AP-1/NF-κB signaling, chondrocyte apoptosis and activation 
of  caspase-3.  Therefore  phytochemicals  may  be  a  beneficial  complementary  treatment  for  OA. 
However, more basic research is required to understand the absorption and bioavailability of these 
compounds and gain a deeper insight into their functional effects. In addition, the basic research needs 
to be followed by well-designed and conducted clinical trials that meet the current expectations of food 
and drug agencies in Europe and North America.  
The European Food Safety Authority (EFSA) [188] based in Parma, Italy has issued new guidelines 
and proposed new scientific requirements for health claims related to the maintenance of joints and to 
the reduction of the risk of developing OA. EFSA has proposed that clinical trials of functional foods 
and  nutraceuticals  should  be  designed  in  new  and  innovative  ways  to  demonstrate  a  ―beneficial 
physiological effect‖ on healthy joints. For example, new guidelines have been introduced for the Int. J. Mol. Sci. 2012, 13  4220 
 
 
substantiation  of  health  claims  related  to  glucosamine  alone  or  in  combination  with  chondroitin 
sulphate  and  maintenance  of  joints  [189].  According  to  regulation  EC  1924/2006  a  ―beneficial 
physiological effect‖ has specific meanings for function and disease risk claims.  
  For function claims: To maintain or to improve a function 
  For reduction of disease risk claims: To reduce a risk factor for the development of a human 
disease (not reduction of the risk of the disease)—a risk factor that may serve as a predictor 
of development of that disease 
According  to  these  new  guidelines  only  clinical  trials  designed  to  demonstrate  a  beneficial 
physiological effect on joints or a reduction in joint degradation in people without OA should be 
accepted  as  indicative.  These  guidelines  present  some  major  new  challenges  to  the  scientific  and 
clinical communities. Furthermore, they create a number of opportunities for new types of clinical 
trials. Since the maintenance of a ―normal joint‖ is considered to be a beneficial physiological effect, 
possible outcomes related to joint structure and function may include changes in:  
  Joint space width on radiographs 
  Mobility 
  Stiffness 
  Joint discomfort (i.e., pain) 
Studies  performed  in  non-diseased  (including  high  risk)  population  subgroups  in  which  the 
incidence of OA is the outcome measure could be used for substantiation of health claims relating to 
the normal maintenance of the joint. Whilst attempting to address these requirements, we need to 
discriminate between food and non-food supplements. Studies dealing with ―non-foods‖ will require a 
much more traditional pharmacological design compared to studies on ―foods‖. Clearly, addressing 
this issue requires new strategies and large scale clinical studies lasting several decades. Such new 
trials will require radical rethinking of the concept of clinical trials in the OA research community. 
Human studies appear to be central for substantiation of clinical data and study groups should be 
representative  of  the  entire  population.  Hierarchy  of  evidence  is  also  considered;  for  example 
interventional studies are of greater significance compared to observational studies and reproducibility 
of the effect much be demonstrated. In addition, demonstrating efficacy of food supplements to EFSA 
will  also  require  data  on  tolerance  and  safety,  specifically  gastric  tolerance,  hepatotoxicity,  renal 
toxicity and allergenicity. Once these important obstacles have been overcome and new clinical trials 
have been carried out, curcumin and resveratrol may become useful alternative adjuncts to the NSAIDs 
that are currently used for the treatment of OA. 
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